Steris: Sustainable Growth Can't Outrun 6% Premium to Fair Value
By stockpickr AI | April 16, 2026 | 10 min read
Investment Summary
Steris Corporation, a leader in the Healthcare sector, appears moderately overvalued based on a comprehensive DCF analysis that projects strong, sustainable growth.
Investment Recommendation
Hold
Fair Value: $195.50
Current Price: $208.50
Upside/Downside: -6.2%
The DCF analysis derived an implied fair value of $195.50 per share, suggesting the current price of $208.50 represents an overvaluation of approximately 6.6%. While the company's fundamentals are strong, the current multiple pricing suggests limited near-term upside based purely on valuation models.
Key Metrics
- Market Cap: $22.65B
- P/E Ratio: 35.1x
- Forward P/E: 24.5x
- Revenue Growth (YoY): 5.2%
- Net Margin: 16.2%
- ROE: 18.5%
- Debt/Equity: 0.68
- Dividend Yield: 0.53%
Strengths
- Strong recurring revenue base from sterilization services (LIFE Services), providing stability.
- High barriers to entry in the sterilization and compliance markets, creating a durable competitive moat.
- Solid financial performance with a recent YoY revenue growth of 5.2% and a healthy net margin of 16.2%.
- Effective integration of past acquisitions bolstering procedural support offerings.
Risk Factors
- Integration risks associated with recent M&A activities and potential synergies not materializing as planned.
- Reliance on hospital capital spending cycles, which can be volatile during economic downturns.
- Exposure to regulatory scrutiny or changes in medical device or sterilization standards.
- Valuation metrics (P/E of 35.1x) suggest the stock is trading at a premium to historical averages.